Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

FB704A placebo

Phase 2

OOneness Biotech Co., Ltd.

FB704A placebo is one of 3 therapeutic programs targeting Severe Asthma. It is currently in Phase 2.

1

Indications

1

Total Trials

0

Active Trials

2

Competitors

Pipeline

Status by Indication[2][1]

Indication

Severe AsthmaCompleted

Severe AsthmaPhase 2

Completed

Competition

Competitive Landscape

2 competitors in Severe Asthma

#DrugCompanyPhaseTrials

Tezspire

FB704A

OOneness Biotech Co., Ltd.

FB704A placebo

OOneness Biotech Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Severe Asthma1 trial

A Randomized, Placebo Controlled, Double Blind Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Multiple Intravenous Doses of FB704A in Adults With Severe Asthma

Completed·OOneness Biotech Co., Ltd.·Phase 2·NCT05018299·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FB704A placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for FB704A placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Oneness Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: OOneness Biotech Co., Ltd.

Related News